Abstract | AIM: METHODS: RESULTS: Reductions in visceral fat, liver fat, skeletal muscle fat and homeostasis model assessment (HOMA)-R due to weight loss were associated with increased Delta insulin 30 min/Delta glucose 30 min (DeltaI30/DeltaG30), and reduced area under the curve (AUC) for plasma glucose as seen in OGTT results. Results from OGTT showed that nateglinide administration was associated with reductions in plasma glucose AUC, both before and after weight loss. Before weight loss, although there was a significant elevation of DeltaI30/DeltaG30 associated with nateglinide treatment, no major change in the insulin-secreting dynamics after glucose loading was observed. After weight loss, nateglinide administration produced a significant increase in DeltaI30/DeltaG30, with insulin secretion peaking more quickly. CONCLUSION:
|
Authors | Y Mori, S Mamori, N Tajima |
Journal | Diabetes, obesity & metabolism
(Diabetes Obes Metab)
Vol. 7
Issue 2
Pg. 182-8
(Mar 2005)
ISSN: 1462-8902 [Print] England |
PMID | 15715891
(Publication Type: Journal Article)
|
Chemical References |
- Blood Glucose
- C-Peptide
- Cyclohexanes
- Fatty Acids, Nonesterified
- Hypoglycemic Agents
- Insulin
- Nateglinide
- Phenylalanine
|
Topics |
- Adipose Tissue
(drug effects)
- Administration, Oral
- Blood Glucose
(analysis)
- C-Peptide
(blood)
- Cyclohexanes
(administration & dosage)
- Fatty Acids, Nonesterified
(blood)
- Female
- Glucose Tolerance Test
- Homeostasis
(drug effects)
- Humans
- Hypoglycemic Agents
(administration & dosage)
- Insulin
(analysis, metabolism)
- Insulin Resistance
(physiology)
- Insulin Secretion
- Liver
(drug effects)
- Male
- Middle Aged
- Muscle, Skeletal
(drug effects)
- Nateglinide
- Obesity
(drug therapy, physiopathology)
- Phenylalanine
(administration & dosage, analogs & derivatives)
- Weight Loss
(physiology)
|